Assessing Prevalence Of Beta Lactamase Production From Clinical Isolates Of Hospitalized Patients And Comparison Of Antibiotic Susceptibility Patterns
EGAST 2008
Expert Group On Antibiotic Susceptibility Testing [EGAST] 2008: A Non-Interventional, Multicenter In-Vitro Study To Evaluate The Prevalence Of Beta-Lactamase Producing Strains Among Clinical Isolates Obtained From Hospital In-Patients And Comparison Of Antimicrobial Susceptibility Using Disc-Diffusion Method
1 other identifier
observational
2,039
1 country
12
Brief Summary
EGAST 2008 is a prospective, non interventional, multicentric study (approximately 2000 isolates from 15- 20 sites). Objectives:
- Comparison of antimicrobial susceptibility using disc-diffusion method
- Assessing prevalence of beta-lactamase producing strains among clinical isolates obtained from hospital in-patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2008
Shorter than P25 for all trials
12 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 4, 2008
CompletedFirst Posted
Study publicly available on registry
August 6, 2008
CompletedStudy Start
First participant enrolled
November 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2009
CompletedMarch 10, 2017
March 1, 2017
10 months
August 4, 2008
March 7, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Comparison of antimicrobial susceptibility using disc-diffusion method
duration of trial
Secondary Outcomes (1)
Assessing prevalence of beta-lactamase producing strains among clinical isolates obtained from hospital in-patients
duration of trial
Eligibility Criteria
Isolates from hospitalised patients
You may qualify if:
- Isolates (as specified in the observational plan) from hospitalised patients
You may not qualify if:
- Isolates obtained from outpatients will not be included for the study. Isolates from repeat cultures performed during in-patient follow-up that were previously recruited into the study will be excluded.
- Isolates identified as commensals or contaminants will be excluded
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (12)
Pfizer Investigational Site
Hyderabad, Andhra Pradesh, 500 082, India
Pfizer Investigational Site
Bangalore, Karnataka, 560 076, India
Pfizer Investigational Site
Bangalore, Karnataka, 560034, India
Pfizer Investigational Site
Manipal, Karnataka, 576 104, India
Pfizer Investigational Site
Mumbai, Maharashtra, 400 016, India
Pfizer Investigational Site
Chandigarh, Punjab, 160 012, India
Pfizer Investigational Site
Porur, Chennai, Tamil Nadu, India
Pfizer Investigational Site
Kolkata, West Bengal, 700 027, India
Pfizer Investigational Site
Kolkata, West Bengal, 700 029, India
Pfizer Investigational Site
Kolkata, West Bengal, 700 098, India
Pfizer Investigational Site
Chennai, 600 006, India
Pfizer Investigational Site
New Delhi, 110 029, India
MeSH Terms
Conditions
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 4, 2008
First Posted
August 6, 2008
Study Start
November 1, 2008
Primary Completion
September 1, 2009
Study Completion
September 1, 2009
Last Updated
March 10, 2017
Record last verified: 2017-03